Skip to content

Confidence in Gambling Disorder: the role of dopamine, incentives and cognitive flexibility

Confidence in Gambling Disorder: the role of dopamine, incentives and cognitive flexibility - Confidence and dopamine in gambling disorder

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55054
Enrollment
60
Registered
2021-03-18
Start date
2021-08-18
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gambling disorder

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: GD group: • DSM-5 diagnosis for Gambling Disorder • No other psychiatric disorders • Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements • 20-55 years of age • Male HC group: • No current psychiatric diagnosis or history of addictions • Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements • 20-55 years of age • Male

Exclusion criteria

Exclusion criteria: All groups: • Current major depressive disorder, bipolar disorder, psychotic disorder, alcohol or substance dependence, or any cognitive disorder as assessed with the MINI neurological disorders section • IQ below 80 • Insufficient command of the Dutch language • MRI contraindications such as metal implants or claustrophobia • Use of dopaminergic ADHD medication, • Endocrinological disorders or regular use of corticosteroids • History of neurological treatment • History of epilepsy • History of autonomic failure • History of clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic or pulmonary disease • Claustrophobia • Current treatment with tricyclic antidepressant or antipsychotic medication • Use of other psychotropic medication, or of recreational drugs over a period of 72 hours prior to each test session, and use of alcohol within the last 24 hours before measurement • Irregular sleep/wake rhythms (e.g. regular nightshifts) Exclusion criteria directly related to PET scanning for both groups: • Participation in a scientific examination where radiation was used, in the last year • Positive urine drug screen on the day of the PET scan. Participants will be tested on cannabis, amphetamine, XTC, cocaine and opiates. Only recent cannabis use will be accepted

Design outcomes

Primary

MeasureTime frame
The main study parameters are: the confidence level in a confidence task, cognitive flexibility in a reversal task, dopamine synthesis capacity and neuromelanin contrast ratio on nMRI scan.

Secondary

MeasureTime frame
1. Age 2. Gender 3. Smoking status 4. IQ 5. Alcohol use 6. Depression symptoms 7. Impulsivity 8. Socioeconomic status

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)